Aevi Genomic Medicine, Inc.
(NASDAQ : GNMX)

( )
GNMX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 7.05%349.560.0%$4455.02m
BNTXBioNTech SE 5.96%294.920.0%$826.74m
NVAXNovavax, Inc. 0.59%135.3579.4%$781.84m
AMGNAmgen, Inc. -0.77%207.631.4%$532.33m
REGNRegeneron Pharmaceuticals, Inc. 0.67%576.202.7%$465.16m
SNSSSunesis Pharmaceuticals, Inc. 2.79%6.260.7%$437.60m
CCXIChemoCentryx, Inc. 1.16%34.972.9%$417.40m
GILDGilead Sciences, Inc. 0.64%67.671.0%$400.74m
ILMNIllumina, Inc. 2.84%420.783.3%$364.05m
XLRNAcceleron Pharma, Inc. -0.10%173.785.3%$349.33m
VRTXVertex Pharmaceuticals, Inc. 0.80%184.991.9%$279.73m
BIIBBiogen, Inc. 1.94%269.941.8%$264.88m
OCGNOcugen, Inc. 12.26%9.340.0%$222.68m
XENEXenon Pharmaceuticals, Inc. -0.42%30.730.4%$173.11m
CRSPCRISPR Therapeutics AG 1.19%96.700.6%$165.13m

Company Profile

Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies. It is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics at The Children's Hospital of Philadelphia.